Koselugo (selumetinib)

Koselugo (selumetinib) is a breakthrough treatment for neurofibromatosis type 1. Explore its impact on pediatric care, accessibility challenges, and healthcare policies.

Cuban Government Uses Child's Medical Case to Showcase Health System, Denies Overseas Transfer

Published on 2/8/2025